NASDAQ:CORT - Corcept Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.97 -0.62 (-4.56 %) (As of 02/24/2020 12:48 PM ET) Add Compare Today's Range$12.96Now: $12.97▼$13.6850-Day Range$11.86MA: $12.96▼$14.0452-Week Range$9.55Now: $12.97▼$17.48Volume18,373 shsAverage Volume827,517 shsMarket Capitalization$1.48 billionP/E Ratio16.63Dividend YieldN/ABeta1.25 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CORT Previous Symbol CUSIP21835210 CIK1088856 Webhttp://www.corcept.com/ Phone650-327-3270Debt Debt-to-Equity RatioN/A Current Ratio8.25 Quick Ratio8.08Price-To-Earnings Trailing P/E Ratio16.63 Forward P/E Ratio13.65 P/E GrowthN/A Sales & Book Value Annual Sales$306.49 million Price / Sales4.84 Cash Flow$0.63 per share Price / Cash Flow20.75 Book Value$2.39 per share Price / Book5.43Profitability EPS (Most Recent Fiscal Year)$0.77 Net Income$94.51 million Net Margins30.73% Return on Equity30.77% Return on Assets27.81%Miscellaneous Employees166 Outstanding Shares114,280,000Market Cap$1.48 billion Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive CORT News and Ratings via Email Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CORT Rates by TradingView Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions What is Corcept Therapeutics' stock symbol? Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT." How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Thursday, February, 20th. The biotechnology company reported $0.24 earnings per share for the quarter, hitting analysts' consensus estimates of $0.24. The biotechnology company had revenue of $87.90 million for the quarter, compared to analyst estimates of $87.85 million. Corcept Therapeutics had a return on equity of 30.77% and a net margin of 30.73%. The company's quarterly revenue was up 31.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.18 EPS. View Corcept Therapeutics' Earnings History. When is Corcept Therapeutics' next earnings date? Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Corcept Therapeutics. What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics updated its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $355-375 million, compared to the consensus revenue estimate of $350.85 million. What price target have analysts set for CORT? 3 brokers have issued twelve-month price objectives for Corcept Therapeutics' stock. Their forecasts range from $15.00 to $20.00. On average, they expect Corcept Therapeutics' share price to reach $17.67 in the next twelve months. This suggests a possible upside of 34.4% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics. What is the consensus analysts' recommendation for Corcept Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corcept Therapeutics. What are Wall Street analysts saying about Corcept Therapeutics stock? Here are some recent quotes from research analysts about Corcept Therapeutics stock: 1. According to Zacks Investment Research, "Corcept is making good progress with its Cushing's syndrome drug Korlym. The drug has witnessed higher sales and strong uptake since its approval. Korlym’s label expansion programs are also promising and should boost its commercial potential in future quarters. Corcept's most advanced candidate relacorilant is currently under evaluation in a phase III study for Cushing's syndrome. The successful development of its pipeline candidates will further boost the company’s growth and lead to increased sales. However, Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will hinder the company’s growth prospects in the future. Shares have outperformed the industry in the past year. Estimates looks stable ahead of Q4 earnings release. Corcept has a positive record of earnings surprises in recent quarters." (2/4/2020) 2. Cantor Fitzgerald analysts commented, "We have a N rating & a $14 PT for CORT based on our valuation of the Korlym + Rela’ franchise. We believe it’s about Rela’ and our question is when will it successfully complete the P3 in Cushing’s & displace Korlym? This thesis is our primary focus since it announced lower-than-projected Korlym rev for 4Q18 & 2019 guidance that points to limited upside potential (~20% midpoint of $285-315M)." (5/1/2019) Has Corcept Therapeutics been receiving favorable news coverage? Media headlines about CORT stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Corcept Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Corcept Therapeutics. Who are some of Corcept Therapeutics' key competitors? Some companies that are related to Corcept Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX). What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), CA (CA), BlackRock (BLK), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Alibaba Group (BABA), Endologix (ELGX), Energy Transfer LP Unit (ET) and Celgene (CELG). Who are Corcept Therapeutics' key executives? Corcept Therapeutics' management team includes the folowing people: Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)Mr. Gary Charles Robb, CFO & Sec. (Age 56)Mr. Sean Maduck, Sr. VP of Commercial (Age 42)Dr. Christopher Shayne James M.D., Director of Investor RelationsDr. Hazel Hunt Ph.D., Sr. VP of Research Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (7.01%), Renaissance Technologies LLC (6.80%), State Street Corp (2.65%), LSV Asset Management (1.50%), Geode Capital Management LLC (1.25%) and Parallel Advisors LLC (1.23%). Company insiders that own Corcept Therapeutics stock include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics. Which major investors are selling Corcept Therapeutics stock? CORT stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Marshall Wace LLP, PNC Financial Services Group Inc., AJO LP, State of New Jersey Common Pension Fund D, Bank of America Corp DE, AQR Capital Management LLC and AlphaCrest Capital Management LLC. View Insider Buying and Selling for Corcept Therapeutics. Which major investors are buying Corcept Therapeutics stock? CORT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, LSV Asset Management, Man Group plc, Mackay Shields LLC, First Trust Advisors LP, Goldman Sachs Group Inc., California Public Employees Retirement System and Parallel Advisors LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics. How do I buy shares of Corcept Therapeutics? Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Corcept Therapeutics' stock price today? One share of CORT stock can currently be purchased for approximately $13.14. How big of a company is Corcept Therapeutics? Corcept Therapeutics has a market capitalization of $1.50 billion and generates $306.49 million in revenue each year. The biotechnology company earns $94.51 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.View Additional Information About Corcept Therapeutics. What is Corcept Therapeutics' official website? The official website for Corcept Therapeutics is http://www.corcept.com/. How can I contact Corcept Therapeutics? Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected] MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 454 (Vote Outperform)Underperform Votes: 380 (Vote Underperform)Total Votes: 834MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/24/2020 by MarketBeat.com StaffFeatured Article: What is the Beige Book?
